## Supplementary Table S1 Characteristics of the participants

| Characteristics | Low (N=9) | High (N=9) | Placebo (N=6) | Total (N=24) |
|----------------|----------|-----------|--------------|--------------|
| Age (years) mean | 65.7 (SD 7.6) | 60.9 (SD 11.8) | 68.7 (SD 6.2) | 64.6 (SD 9.3) |
| Sex [female; n (%)] | 4 (44%) | 2 (22%) | 0 (0%) | 6 (25%) |
| Hispanic or Latino | 0 (0%) | 0 (0%) | 1 (17%) | 1 (4%) |
| Race [n (%)] | | | | |
| Asian | 2 (22%) | 1 (11%) | 1 (17%) | 4 (17%) |
| White | 7 (78%) | 8 (89%) | 5 (83%) | 20 (83%) |
| Height (cm) mean | 168.9 (SD 11.3) | 176.3 (SD 10.1) | 177.2 (SD 7.9) | 173.8 (SD 10.4) |
| Weight (kg) mean | 80.52 (SD 11.39) | 86.57 (SD 10.80) | 86.90 (SD 5.70) | 84.38 (SD 10.10) |
| BMI (kg/m²) mean | 28.26 (SD 3.40) | 27.89 (SD 3.24) | 27.78 (SD 2.36) | 28.00 (SD 2.99) |

Low: low dose of AGMG0201; High: high dose of AGMG0201; Placebo: Saline